Onjisaponin B
Based on 2 publication(s) in Google Scholar
Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.31%
- CAS No.: 35906-36-6
- 화학식: C75H112O35
- 분자량:1573.67
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Onjisaponin B
MoreAll Caspase Isoforms
More
Biological Activity
Onjisaponin B (3-50 μM, 8-24 h) activates autophagy through an Atg7, AMPK-mTOR dependent manner in PC-12 cells[1].
Onjisaponin B (6.25-50 μM, 16-24 h) enhances the clearance of mutant huntingtin and A53T α-synuclein, lowers the toxicity and acts as a neuroprotective agent in PC-12 cells, and reduces oligomerization of α-synuclein in HeLa cells[1].
Onjisaponin B (0.01-10 μM) reducesβ-amyloid (Aβ) production with an IC50 of 10 μM without affecting BACE1 or γ-secretase activity in 293T cells[3].
Onjisaponin B (20 μg/mL, 8-50 h) inhibits the activation of Cas3 through p65, reducing radiation-induced cell apoptosis and helping to prevent radiation injury in TC, V79 and MTEC-1 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC-12 cells transfected with GFP-LC3 plasmids
-
Concentration:6.25, 12.5, 25, 50 μM
-
Incubation Time:24 h
-
Result:Increased the formation of GFP-LC3 puncta formation in a dose-dependent manner.
-
Cell Line:PC-12 cells transfected transiently with EGFP-HDQ 74 or myc-tagged mutant A53T α-synuclein
-
Concentration:25 μM or 50 μM
-
Incubation Time:48 h or 24 h
-
Result:Reduced toxicity in PC-12 cells expressing either mutant huntingtin or A53T α-synuclein.
-
Cell Line:TC cells(thymocytes), V79 cells, MTEC-1 cells
-
Concentration:20 μg/mL
-
Incubation Time:8, 50, 26 h (incubated 2 hours then irradiated with radiation (TC cells: 6 h, V79 cells: 48 h, MTEC-1 cells: 24 h))
-
Result:Reduced apoptosis caused by radiotherapy.
-
Cell Line:PC-12 cells
-
Concentration:3, 6.25, 12.5, 25, 50 μM
-
Incubation Time:8, 16, 24 h
-
Result:Increased the rate of LC3-II formation with the presence of protease inhibitors.
No obvious cytotoxicity observed.
Activated the phosphorylation of AMPK in a time- and dose-dependent manner, and the activation was accompanied by a concomitant reduction in its downstream p70S6K phosphorylation.
-
Cell Line:V79 cells
-
Concentration:20 μg/mL
-
Incubation Time:2 hours prior to irradiation
-
Result:Down regulated the expression levels of the activation products p-p65 and c-Cas3 induced by irradiation.
The ability to down-regulate p-p65 and c-Cas3 proteins was reduced, or even reversed in V79 cells transfected with p65 shRNA plasmid.
Onjisaponin B (20-40 mg/kg; i.g.; daily for 12 days) ameliorates dopaminergic (DA) neurodegeneration in a MPTP (HY-15608)-induced mouse model of Parkinson’s disease (PD) through anti-oxidant and anti-inflammatory activities mediated via the RhoA/ROCK2 signaling pathway[2].
Onjisaponin B (10 mg/kg; p.o.; daily from 4 to 7 months of age) reduces β-amyloid production and improve cognitive impairments in transgenic mice[3].
Onjisaponin B (2.5 mg/kg; p.o.; 4 days prior to irradiation) significantly reduces pathological changes and apoptosis and the nuclear translocation of p65 in the lung tissue of p65+/- mice following radiation[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J-Relaem1Smoc mice (p65+/- mice)[4]
-
Dosage:2.5 mg/kg
-
Administration:Oral gavage (p.o.); 4 days prior to irradiation
-
Result:Inhibited p65 and cas3 activation caused by p65, and significantly reduced pathological changes and apoptosis (caused by down-regulation of p65) and the nuclear translocation of p65 in the lung tissue of p65+/- mice following radiation, but not in the thymus.
-
Animal Model:C57BL/6J mice (male, 12 weeks old)[2]
-
Dosage:20, 40 mg/kg
-
Administration:Intragastric gavage (i.g.); daily for 12 days
-
Result:Had a neuroprotective effect on MPTP (HY-15608) induced Parkinson’s disease (PD) model mice.
Recovered MPTP-induced motor impairment.
Reduced the number of ionized calcium-binding adapter molecule 1 (IBA-1)-positive cells, suppressed microglial activation induced by MPTP.
Inhibited the secretion of IL-1β, TNF-α, and IL-6.
Decreased MDA levels but increased SOD levels, exerted antioxidant abilities in PD model mice.
-
Animal Model:APPswe/PS1ΔE9 (APP/PS1) double-transgenic mice[3]
-
Dosage:10 mg/kg (200 μL (1 mg/mL) per 20 g body weight)
-
Administration:Oral gavage (p.o.); daily from 4 to 7 months of age
-
Result:No obvious toxic effects in mice.
Did not alter mouse locomotor activity.
Ameliorated cognitive impairments in amyloid precursor protein (APP)/ presenilin 1 (PS1) mice.
Showed significantly lower numbers of 6E10-positive Aβ plaque and reduced plaque area.
Chemical Information
-
CAS No. 35906-36-6
-
Appearance Solid
-
분자량 1573.67
-
화학식 C75H112O35
-
Color White to off-white
-
SMILES
OC[C@](C1=CC[C@]2([H])[C@]3(C[C@H](O)[C@@H]4O[C@]([C@@H]([C@@H](O)[C@@H]5O)O)([H])O[C@@H]5CO)C)(CC[C@]6(C(O[C@H](O[C@H](C)[C@H](OC(/C=C/C7=CC=C(OC)C=C7)=O)[C@@H]8O[C@@](O[C@@H](C)[C@H](O)[C@H]9O)([H])[C@@H]9O)[C@@H]8O[C@@](O[C@@H](C)[C@H](O[C@@](OC[C@@H](O[C@]([C@@H]([C@@H](O)[C@H]%10O)O)([H])O[C@@H]%10CO)[C@@H]%11O)([H])[C@@H]%11O)[C@H]%12O)([H])[C@@H]%12O)=O)[C@@]1([H])CC(C)(C)CC6)[C@@]2(CC[C@@]3([H])[C@]4(C)C(O)=O)C
-
Synonyms
Senegin III
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
EMBO Mol Med
Reelin-LRP8 signaling mediates brain dissemination of breast cancer cells via abluminal migration. [Abstract]2025 Jun 12. PMID: 40506610 -
Biochem Biophys Res Commun
Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads. [Abstract]2025 Aug 30:776:152184. PMID: 40517671
용액&용해도
DMSO : 100 mg/mL (63.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (1.59 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (291 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wu AG, et al. Onjisaponin B derived from Radix Polygalae enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells. Int J Mol Sci. 2013 Nov 15;14(11):22618-41. [Content Brief]
[2]. Peng F, et al. The onjisaponin B metabolite tenuifolin ameliorates dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Neuroreport. 2020 Apr 8;31(6):456-465. [Content Brief]
[3]. Li X, et al. Traditional Chinese Nootropic Medicine Radix Polygalae and Its Active Constituent Onjisaponin B Reduce β-Amyloid Production and Improve Cognitive Impairments. PLoS One. 2016 Mar 8;11(3):e0151147. [Content Brief]
[4]. Wang TY, et al. Targeting p65 to inhibit Cas3 transcription by Onjisaponin B for radiation damage therapy in p65+/- mice. Phytomedicine. 2022 Sep;104:154317. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6355 mL | 3.1773 mL | 6.3546 mL | 15.8864 mL |
| 5 mM | 0.1271 mL | 0.6355 mL | 1.2709 mL | 3.1773 mL | |
| 10 mM | 0.0635 mL | 0.3177 mL | 0.6355 mL | 1.5886 mL | |
| 15 mM | 0.0424 mL | 0.2118 mL | 0.4236 mL | 1.0591 mL | |
| 20 mM | 0.0318 mL | 0.1589 mL | 0.3177 mL | 0.7943 mL | |
| 25 mM | 0.0254 mL | 0.1271 mL | 0.2542 mL | 0.6355 mL | |
| 30 mM | 0.0212 mL | 0.1059 mL | 0.2118 mL | 0.5295 mL | |
| 40 mM | 0.0159 mL | 0.0794 mL | 0.1589 mL | 0.3972 mL | |
| 50 mM | 0.0127 mL | 0.0635 mL | 0.1271 mL | 0.3177 mL | |
| 60 mM | 0.0106 mL | 0.0530 mL | 0.1059 mL | 0.2648 mL |
Onjisaponin B Related Classifications
HY-N2099 Related Classifications
Powered by Bioz